Table 3.

Characteristics of some single-cell sequencing datasets. The number of samples is per patient. The number of cells, also per patient, only includes those which passed quality control and were used for mutation calling. The false positive and allelic drop out rate estimates are per genomic position. The number of mutations excludes those which only occur in one cell which are uninformative for the phylogenetic reconstruction. They may however include mutations occurring (or with missing data) in all cells which are also uninformative. These have been removed from the count of [70] and do not occur for the ER ⁺ tumour of [78] on in any of the patient samples from [80].

Cancer type	Year and reference	Number of patients	Number of samples	Number of mutations	Number of cells	False positive rate	Allelic drop out rate	Missing data
Myeloproliferative neoplasm	(2012) [69]	1	1	712	58	6.04 ×10 −5	0.4309	58%
Kidney	(2012) [70]	1	1	35	17	2.67 ×10 −5	0.1643	22%
Bladder	(2012) [71]	1	1	443	44	6.7 × 10 −5	0.4	55%
Colon	(2014) [87]	1	1	176	63	<1 ×10 −4	>0.5	–
Breast	(2014) [78]	2	1	40/519	47/16	1.24 ×10 −6	0.0973	1%
Leukemia	(2014) [77]	3	1	≤ 1953a	11–12	–	0.12	28%
Leukemia	(2014) [80]	6	1	10–105	96–150	–	≤ 0.3	–
Breast (and xenografts)	(2015) [50]	2	2/3	37/45b	120/90	–	≈ 0.2	7–12%
Ovarian (intraperitoneal)	(2016) [97]	3	4–5	23–33b	420–672	–	–	–

^aThe number of mutations listed for [77] refers to the number of loci sequenced.

^bThe number of mutations only indicates those uncovered in targeted panels of 40/45 SNVs for [50] and of 43–84 SNVs for [97].